Samos Pharmaceuticals

Siduma Therapeutics, formerly known as Samos Pharmaceuticals, is a biotechnology company focused on the development of next-generation targeted protein degradation (TPD) therapies. Founded by Yale University professor Craig Crews, a pioneer in the field of PROTACs, the company aims to address "undruggable" targets in oncology. Siduma's proprietary platform utilizes a novel mechanism of action to induce the degradation of disease-causing proteins that are inaccessible to traditional small molecule inhibitors. The company is currently in the pre-clinical stage, advancing a pipeline of candidates designed to provide more effective treatment options for patients with various forms of cancer.